GO:0035594 ganglioside binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035594 ganglioside binding is a molecular function defined as binding to a ganglioside, a ceramide oligosaccharide carrying one or more sialic acid residues.
• Ganglioside binding is mediated by conserved structural domains, including sialic acid-binding immunoglobulin-like lectins (siglecs) and ganglioside-binding domains found in bacterial toxins and amyloid peptides [1,7,6].
• Key proteins with ganglioside-binding activity include CD33-related siglecs, botulinum neurotoxins, E. coli enterotoxins, and amyloid-beta (Aβ42) [7,2,8,6].
• Ganglioside binding is implicated in host-pathogen interactions, neurotoxin entry, immune modulation, and neurodegenerative processes such as Alzheimer's disease [1,3,6].
• Experimental approaches to study ganglioside binding include biomembrane-based bioelectronic sensors, density gradient ultracentrifugation, and cell adhesion assays [4,6,3].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of ganglioside-binding proteins in disease and infection.
Description
Ganglioside binding (GO:0035594) is a molecular function that describes the selective interaction of proteins or peptides with gangliosides, which are sialic acid-containing glycosphingolipids embedded in cell membranes. This binding event is central to diverse biological processes, including cell recognition, signal transduction, and pathogen entry [1,2]. The QuickGO definition specifies that ganglioside binding involves a ceramide oligosaccharide carrying one or more sialic acid residues, highlighting the importance of both the lipid moiety and the sialic acid residues for recognition. Researchers study ganglioside binding to understand mechanisms of neurotoxicity, immune regulation, and host-microbe interactions [1,7,8]. For example, botulinum neurotoxins C and D-SA exhibit unique ganglioside binding specificities that influence their cellular targets. Similarly, CD33-related siglecs display distinct ganglioside binding patterns that modulate immune cell signaling. The amyloid-beta peptide Aβ42 binds to ganglioside-containing membranes, a process linked to Alzheimer's disease pathology. These examples underscore the broad relevance of ganglioside binding across physiology and disease.
ganglioside binding At A Glance
| GO ID | GO:0035594 |
|---|---|
| GO term | ganglioside binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a ganglioside, a ceramide oligosaccharide carrying in addition to other sugar residues, one or more sialic acid residues. |
| Major function | Mediates protein-carbohydrate recognition at membrane surfaces, involved in cell signaling, pathogen entry, and immune modulation. |
| Representative proteins | CD33-related siglecs, botulinum neurotoxins, E. coli enterotoxins, amyloid-beta peptide. |
| Associated diseases | Alzheimer's disease, bacterial intoxication, inflammatory responses. |
| Research methods | Bioelectronic sensors, density gradient ultracentrifugation, cell adhesion assays, CRISPR screens. |
What Is GO:0035594?
Ganglioside binding is the molecular function of selectively and non-covalently interacting with a ganglioside, which is a glycosphingolipid composed of a ceramide lipid moiety linked to an oligosaccharide chain that includes one or more sialic acid residues. This binding typically involves recognition of the carbohydrate headgroup, particularly the sialic acid moieties, and can be influenced by the lipid environment [1,6].
Why Is ganglioside binding Important in Cell Biology?
Ganglioside binding is important because it governs critical interactions between proteins and the cell membrane, influencing processes ranging from neuronal signaling to immune recognition and infection. Dysregulation of ganglioside binding is associated with neurodegenerative diseases, such as Alzheimer's disease, where Aβ42 binding to gangliosides promotes aggregation and toxicity. Bacterial toxins, including botulinum neurotoxins and E. coli enterotoxins, exploit ganglioside binding for host cell entry and pathogenesis [2,8]. Additionally, CD33-related siglecs modulate immune responses through ganglioside recognition, with implications for autoimmune and inflammatory conditions. Understanding ganglioside binding at the molecular level can inform therapeutic strategies targeting these interactions [1,3].
• Mediates host-pathogen interactions by serving as a receptor for bacterial toxins and viruses [1,2].
• Regulates immune cell signaling through CD33-related siglecs.
• Contributes to Alzheimer's disease pathogenesis via Aβ42-ganglioside binding.
• Influences neurotoxin specificity and potency, as seen with botulinum neurotoxins C and D-SA.
• Plays a role in enterotoxigenic E. coli adhesion and inflammatory responses.
• Provides targets for therapeutic intervention in infectious and neurodegenerative diseases.
• Enables development of biosensors for detecting ganglioside-binding toxins.
• Relevant to muscle physiology through ganglioside-binding proteins in skeletal and cardiac muscle.
• Facilitates study of membrane microdomains and lipid rafts.
• Offers a model system for studying protein-carbohydrate recognition.
Molecular Mechanism of ganglioside binding
Recognition of sialic acid residues
In simple terms: Proteins bind to the sialic acid sugars on gangliosides.
The initial step in ganglioside binding involves specific recognition of sialic acid residues on the ganglioside carbohydrate headgroup. Proteins such as CD33-related siglecs use their V-set immunoglobulin domains to interact with sialic acid, with specificity determined by the linkage and number of sialic acids. Botulinum neurotoxins C and D-SA exhibit unique ganglioside binding profiles, preferring gangliosides with specific sialic acid configurations. This recognition is often stabilized by hydrogen bonding and electrostatic interactions.
Interaction with the lipid environment
In simple terms: The membrane lipid composition affects how well proteins bind to gangliosides.
Ganglioside binding is modulated by the surrounding lipid environment, particularly cholesterol and sphingomyelin. The binding of Aβ42 peptide monomers to sphingomyelin/cholesterol/ganglioside bilayers is influenced by lipid composition, as assayed by density gradient ultracentrifugation. This suggests that membrane microdomains (lipid rafts) enriched in gangliosides facilitate binding and subsequent signaling events.
Structural domains involved in binding
In simple terms: Specific protein domains are responsible for attaching to gangliosides.
Several protein domains mediate ganglioside binding, including the ganglioside-binding domain found in bacterial toxins and the sialic acid-binding immunoglobulin-like lectin (siglec) domains [1,7]. For example, E. coli enterotoxins LT-IIb and its variant LT-IIb(T13I) display distinct ganglioside-binding specificities mediated by their B subunits. The GM1a ganglioside-binding domain peptide from heat-labile enterotoxin B inhibits host adhesion and inflammatory responses in HCT-8 cells.
Functional consequences of binding
In simple terms: Binding triggers various cellular responses.
Ganglioside binding can lead to diverse functional outcomes, including toxin internalization, immune cell activation or inhibition, and peptide aggregation. Botulinum neurotoxin binding to gangliosides facilitates neuronal entry. CD33-related siglec binding to gangliosides can modulate immune signaling. Aβ42 binding to gangliosides promotes aggregation, a hallmark of Alzheimer's disease. These downstream effects highlight the physiological and pathological significance of ganglioside binding.
Detection and quantification methods
In simple terms: Scientists use specialized tools to measure ganglioside binding.
Ganglioside binding can be detected using biomembrane-based bioelectronic sensors, which enable real-time monitoring of toxin-ganglioside interactions. Density gradient ultracentrifugation allows assessment of peptide binding to ganglioside-containing liposomes. Cell adhesion assays and inflammatory response measurements are used to evaluate functional consequences of ganglioside binding in vitro.
Key Genes Involved in GO:0035594 ganglioside binding
The following genes and proteins are representative of ganglioside-binding activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD33 | Siglec family member; binds sialic acid-containing gangliosides | Immune regulation; target for Alzheimer's disease |
| SIGLEC7 | CD33-related siglec; ganglioside binding | Immune modulation; natural killer cell inhibition |
| SIGLEC9 | CD33-related siglec; ganglioside binding | Inflammatory responses; neutrophil function |
| SIGLEC11 | CD33-related siglec; ganglioside binding | Microglial function; neuroinflammation |
| Bont/C | Botulinum neurotoxin C; ganglioside binding | Neurotoxin entry; therapeutic applications |
| Bont/D-SA | Botulinum neurotoxin D-SA; ganglioside binding | Neurotoxin specificity |
| eltB | E. coli heat-labile enterotoxin B subunit; GM1 binding | Enterotoxigenic E. coli pathogenesis |
| LT-IIb | E. coli type II enterotoxin; ganglioside binding | Host-pathogen interactions |
| APP | Amyloid precursor protein; source of Aβ42 | Alzheimer's disease; ganglioside binding |
| Aβ42 | Amyloid-beta peptide; binds gangliosides | Neurodegeneration; aggregation |
| GM1a | Ganglioside; binding target | Cell adhesion; inflammation |
| GD1a | Ganglioside; binding target | Neurotoxin receptor |
| GT1b | Ganglioside; binding target | Neurotoxin receptor |
| GQ1b | Ganglioside; binding target | Neurotoxin receptor |
| Sialic acid | Carbohydrate moiety of gangliosides | Recognition determinant |
| Ceramide | Lipid moiety of gangliosides | Membrane anchoring |
| Cholesterol | Membrane lipid; modulates ganglioside binding | Lipid raft formation |
| Sphingomyelin | Membrane lipid; modulates ganglioside binding | Lipid raft formation |
How Is ganglioside binding Regulated?
Ganglioside binding is regulated at multiple levels, including the availability of gangliosides in the membrane, the lipid composition of the membrane, and post-translational modifications of the binding proteins. For instance, the binding of Aβ42 to gangliosides is influenced by the presence of cholesterol and sphingomyelin, which affect membrane fluidity and ganglioside clustering. Additionally, siglec-mediated ganglioside binding can be modulated by sialic acid modifications and cis-interactions with other glycans. Bacterial toxin binding to gangliosides may be regulated by environmental factors such as pH and temperature.
ganglioside binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease; Aβ42 aggregation | Knockout or point-mutation of APP in neuronal cells; ganglioside binding assays |
| CD33 | Immune regulation; Alzheimer's disease risk | Knockout or overexpression of CD33 in microglial cells; siglec binding assays |
| eltB | Enterotoxigenic E. coli infection | Knockout of eltB in E. coli; HCT-8 cell adhesion assays |
| Bont/C | Botulism; neurotoxicity | Point mutations in botulinum neurotoxin C; ganglioside binding studies |
| LT-IIb | E. coli enterotoxin; host interaction | Knock-in of LT-IIb variants; ganglioside binding specificity assays |
Alzheimer's disease
Ganglioside binding by amyloid-beta (Aβ42) is implicated in Alzheimer's disease pathogenesis. Aβ42 monomers bind to ganglioside-containing membranes, promoting aggregation and neurotoxicity. This interaction is enhanced by cholesterol and sphingomyelin, which are components of lipid rafts. Targeting ganglioside binding may offer therapeutic avenues for Alzheimer's disease.
Bacterial infections and intoxication
Many bacterial toxins exploit ganglioside binding for host cell entry. Botulinum neurotoxins C and D-SA bind gangliosides with unique specificities, facilitating neuronal intoxication. Enterotoxigenic E. coli heat-labile enterotoxin binds GM1a ganglioside, contributing to adhesion and inflammatory responses in intestinal cells. LT-IIb and its variant LT-IIb(T13I) exhibit distinct ganglioside-binding patterns that influence host-pathogen interactions.
Immune regulation and inflammation
CD33-related siglecs bind gangliosides and modulate immune cell signaling. This binding can inhibit or activate immune responses, with implications for autoimmune diseases and cancer. For example, siglec-7 and siglec-9 recognize gangliosides on target cells, influencing natural killer cell activity and neutrophil function. Dysregulated ganglioside binding may contribute to chronic inflammation.
From ganglioside binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CD33 affect ganglioside binding and immune signaling? | CD33 knockout in microglial cell lines or primary cells |
| How do point mutations in botulinum neurotoxin affect ganglioside specificity? | Point-mutant knock-in of Bont/C or Bont/D-SA in neuronal cells |
| Can ganglioside-binding domain peptides inhibit enterotoxin adhesion? | Overexpression of GM1a-binding peptide in HCT-8 cells |
| What is the role of Aβ42 ganglioside binding in aggregation? | Knock-in of mutant APP or Aβ42 in neuronal cells; ganglioside binding assays |
| How does lipid composition affect ganglioside binding? | Knockout of cholesterol/sphingomyelin synthesis genes; lipid raft analysis |
| Can siglec ganglioside binding be modulated by sialic acid modifications? | Overexpression of siglecs with altered sialylation in immune cells |
How to Study the ganglioside binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Bioelectronic sensor | Real-time binding kinetics | Detection of toxin-ganglioside interactions |
| Density gradient ultracentrifugation | Peptide binding to liposomes | Aβ42-ganglioside binding studies |
| Cell adhesion assay | Host cell attachment | Enterotoxigenic E. coli adhesion |
| Inflammatory cytokine assay | Immune response | Ganglioside-binding peptide effects |
| CRISPR knockout screening | Gene requirement for binding | Identification of novel ganglioside-binding proteins |
| Surface plasmon resonance | Binding affinity and kinetics | Protein-ganglioside interaction analysis |
| Flow cytometry | Cell surface ganglioside binding | Siglec-ganglioside interaction |
| Structural modeling | Binding interface prediction | Design of ganglioside-binding inhibitors |
Biomembrane-based bioelectronic sensors
Biomembrane-based bioelectronic sensors enable label-free, real-time detection of ganglioside binding by toxins and other proteins. These sensors incorporate gangliosides into lipid bilayers on electronic transducers, allowing quantification of binding affinity and kinetics.
Density gradient ultracentrifugation
Density gradient ultracentrifugation is used to assay the binding of peptides such as Aβ42 to sphingomyelin/cholesterol/ganglioside bilayers. This method separates bound from unbound peptides based on density, providing quantitative data on binding efficiency.
Cell adhesion and inflammatory response assays
Cell adhesion assays measure the ability of ganglioside-binding proteins to mediate attachment of bacteria or cells to host cells. Inflammatory response assays, such as cytokine measurement, assess downstream effects of ganglioside binding in cell culture models.
CRISPR screening and bioinformatics
CRISPR library screening can identify genes required for ganglioside binding and downstream signaling. Bioinformatics analysis of glycan-binding domains and structural modeling further elucidates binding mechanisms.
How CRISPR Can Be Used to Study GO:0035594 ganglioside binding
Knockout
CRISPR knockout of genes encoding ganglioside-binding proteins (e.g., CD33, APP) allows researchers to assess loss-of-function effects on ganglioside binding, downstream signaling, and disease phenotypes [1,7]. Knockout of toxin genes (e.g., eltB) in bacteria can confirm their role in host cell binding.
Point Mutation
Point mutations introduced via CRISPR can dissect the specific amino acid residues required for ganglioside binding. For example, mutations in the sialic acid-binding pocket of siglecs or botulinum neurotoxins can alter binding specificity and affinity [2,7].
Knock-in
Knock-in of mutant or variant ganglioside-binding proteins (e.g., LT-IIb(T13I)) enables study of altered binding specificities in relevant cell types. This approach can model human disease-associated variants or pathogen variants.
Overexpression
Overexpression of ganglioside-binding proteins or domains (e.g., GM1a-binding peptide) can enhance binding and reveal downstream effects, such as inhibition of host adhesion and inflammation. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports ganglioside binding Research
Researchers studying ganglioside binding-related genes often need to determine whether a candidate gene is causally involved in binding, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of ganglioside-binding proteins and their roles in health and disease.
Contact EDITGENE today to design your custom CRISPR model for ganglioside binding research.
Frequently Asked Questions About ganglioside binding
What is ganglioside binding?
Ganglioside binding is a molecular function (GO:0035594) involving the selective interaction of proteins with gangliosides, which are sialic acid-containing glycosphingolipids.
What genes are involved in ganglioside binding?
Key genes include CD33, SIGLEC7, SIGLEC9, SIGLEC11, APP, and bacterial toxin genes such as eltB and Bont/C [7,6,3,2].
What diseases are associated with ganglioside binding?
Ganglioside binding is linked to Alzheimer's disease, bacterial infections, and immune disorders [6,3,7].
How is ganglioside binding studied?
Common methods include bioelectronic sensors, density gradient ultracentrifugation, cell adhesion assays, and CRISPR screens [4,6,3].
What is the role of ganglioside binding in Alzheimer's disease?
Aβ42 binding to gangliosides promotes aggregation and neurotoxicity, contributing to Alzheimer's pathology.
Which proteins have ganglioside-binding domains?
Proteins such as CD33-related siglecs, botulinum neurotoxins, and E. coli enterotoxins contain ganglioside-binding domains [7,2,8].
How does ganglioside binding affect immune cells?
Siglec-ganglioside binding modulates immune cell signaling, influencing activation and inhibition.
Can ganglioside binding be targeted therapeutically?
Yes, inhibiting ganglioside binding is a potential strategy for treating infections and neurodegenerative diseases [1,3].
What is the QuickGO definition of ganglioside binding?
Binding to a ganglioside, a ceramide oligosaccharide carrying in addition to other sugar residues, one or more sialic acid residues.
What model systems are used to study ganglioside binding?
Cell lines, primary neurons, microglia, and bacterial cells are commonly used, often with CRISPR engineering [1,7,3].
Conclusion
Ganglioside binding (GO:0035594) is a fundamental molecular function with broad implications for cell signaling, host-pathogen interactions, and neurodegeneration. The diverse proteins and mechanisms involved, from siglecs to bacterial toxins and amyloid peptides, highlight its biological importance [1,7,2,6]. Continued research using advanced CRISPR models and detection technologies will further elucidate its roles and therapeutic potential [4,3].
References
- 1. Azzaz F et al.. 2022. Ganglioside binding domains in proteins: Physiological and pathological mechanisms.. Adv Protein Chem Struct Biol 128:289-324 PMID: 35034721
- 2. Kroken AR et al.. 2011. Unique ganglioside binding by botulinum neurotoxins C and D-SA.. FEBS J 278(23):4486-96 PMID: 21554541
- 3. Park JY et al.. 2023. GM1a ganglioside-binding domain peptide inhibits host adhesion and inflammatory response of enterotoxigenic Escherichia coli heat-labile enterotoxin-B in HCT-8 cells.. Sci Rep 13(1):16835 PMID: 37803175
- 4. Bint E Naser SF et al.. 2021. Detection of Ganglioside-Specific Toxin Binding with Biomembrane-Based Bioelectronic Sensors.. ACS Appl Bio Mater 4(11):7942-7950 PMID: 35006775
- 5. Chan KF et al.. 1991. Ganglioside-binding proteins in skeletal and cardiac muscle.. Glycobiology 1(2):193-203 PMID: 1823162
- 6. Ahyayauch H et al.. 2020. The Binding of Aβ42 Peptide Monomers to Sphingomyelin/Cholesterol/Ganglioside Bilayers Assayed by Density Gradient Ultracentrifugation.. Int J Mol Sci 21(5) PMID: 32121399
- 7. Rapoport E et al.. 2003. Ganglioside binding pattern of CD33-related siglecs.. Bioorg Med Chem Lett 13(4):675-8 PMID: 12639556
- 8. Berenson CS et al.. 2010. Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I).. Glycobiology 20(1):41-54 PMID: 19749203
